Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography

European Journal of Pharmacology

Volumn 295, Issue 1, 1996, Pages 35-44

  Abadie, Pascale ^a   Rioux, Patrice ^a   Scatton, Bernard ^b   Zarifian, Edouard ^a   Barré, Louisa ^a   Patat, Alain ^b   Baron, Jean Claude ^a,c  

^a UNIVERSITÉ DE CAEN   (France)

^b SANOFI   (France)

^c GIP CYCERON   (France)

Author keywords

Benzodiazepine receptor, central; Imidazopyridine; PET (positron emission tomography); 11C Flumazenil

Indexed keywords

BENZODIAZEPINE RECEPTOR; CARBON 11; FLUMAZENIL; ZOLPIDEM;

ADULT; ARTICLE; BRAIN REGION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEOCORTEX; NORMAL HUMAN; OCCIPITAL CORTEX; ORAL DRUG ADMINISTRATION; PARIETAL LOBE; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; TEMPORAL CORTEX; VOLUNTEER;

EID: 0030027545     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00633-8     Document Type: Article

References (41)

1. Abadie, P. and J.C. Baron, 1990, In vivo studies of the central benzodiazepine receptors in the human brain with positron emission topography, in: Radiopharmaceuticals and Brain Pathology Studied with PET and SPECT, eds. M. Diksic and R.C. Reba (CRC Press, Boca Raton) p. 357.
2. d values with positron emission tomography, Eur. J. Pharmacol. 213, 115.
3. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders, 3rd edn., revised (DSM III R). Washington D.C.
4. 3H]zolpidem binding in the rat brain: an imidazopyridine with agonist properties at central benzodiazepine receptors, Eur. J. Pharmacol. 130, 257.
5. 11C]Ro 15 1788 (flumazenil) from its metabolites in the blood of rabbits, baboons and humans, Appl. Radiat. Isot. 42, 435.
6. 1) subtype, J. Pharmacol. Exp. Ther. 245, 1033.
7. 3H]flumazenil binding in the rat central nervous system, J. Pharmacol. Exp. Ther. 263, 884.
8. Benavides, J., B. Peny, D. Ruano, J. Vitorica and B. Scatton, 1993, comparative autoradiographic distribution of central to (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem, Brain Res. 604, 240.
9. Cudennec, A., M. Decobert, H. Depoortere, D. Duverger, E.T. Mackenzie and A.R. Young, 1988, The effects of an imidazopyridine hypnotic, zolpidem, on cerebral blood flow and metabolism in primates and rats, in: Imidazopyridines in Sleep Disorders, eds. J.P. Sauvanet, S.Z. Langer and P.L. Morselli (Raven Press, New York) p. 379.
10. 11C]Ro 15 1788 (flumazenil) in baboon and human during positron emission tomography studies, Eur. J. Drug Metab. Pharmacokin. 16, 141.
11. 11C]flumazenil kinetics in human brain using the multi-injection approach, J. Cereb. Blood Flow Metab. 13, Suppl. 1, S791.
12. 3H]flunitrazepam, J. Pharmacol. Exp. Ther. 247, 309.
13. Depoortere, H., B. Zivkovic, K.G. Lloyd, D.J. Sanger, G. Perrault, S.Z. Langer and G. Bartholini, 1986, Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioural effects, J. Pharmacol. Exp. Ther. 237, 649.
14. Durand, A., J.P. Thenot, G. Bianchetti and P.L. Morselli, 1992, Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem, Drug Metab. Rev. 24, 239.
15. Facklam, M., P. Schoch, E.P. Bonetti, F. Jenck, J.R. Martin, J.L. Moreau and W.E. Haefely, 1992, Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies, J. Pharmacol. Exp. Ther. 261, 1113.
16. Forster, A., O. Juge, M. Louis and A. Nahory, 1987, Effects of a specific benzodiazepine antagonist (Ro 15-1788) on cerebral blood flow, Anesth. Analg. 66, 309.
17. Fox, P.T., J.S. Perlmutter, and M.E. Raichle, 1985, A stereotactic method of anatomical localization for positron emission tomography, J. Comput. Ass. Tomog. 9, 141.
18. Guinebault, P., C. Dubruc, P. Hermann and J.P. Thenot, 1986, High performance liquid chromatography determination of zolpidem, a new sleep inducer, in biological fluids with fluorometric detection, J. Chromatog. 383, 206.
19. Hantraye, P., M. Kaijima, C. Prenant, B. Guibert, J. Sastre, M. Crouzel, R. Naquet, D. Comar and M. Mazière, 1984, Central type benzodiazepine binding site: a positron emission tomography study in the baboon's brain, Neurosci. Lett. 48, 115.
20. Ito, K., Y. Yamada, K. Nakamura, Y. Sawada and T. Iga, 1993, Classification of benzodiazepine hypnotics in humans based on receptor occupancy theory, J. Pharmacokin. Biopharm. 21, 31.
21. Langtry, H.D. and P. Benfield, 1990, Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential, Drugs 2, 291.
22. Lassen, N.A., 1992, Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers, J. Cereb. Blood Flow Metab. 12, 709.
23. Litton, J.E., H. Hall and S. Pauli, 1994, Saturation analysis in PET. Analyses of errors due to imperfect reference regions, J. Cereb. Blood Flow Metab. 14, 358.
24. Maloteaux, J.M., J.N. Octave, M.A. Vanisberg, P. Kollmann, A. Ackermans and C. Laterre, 1988, Benzodiazepine receptors in human brain: characterization, subcellular localization and solubilization, Prog. Neuro-Psychopharmacol. Biol. Psychiat. 12, 773.
25. Mazière, M., P. Hantraye, C. Prenant, J. Sastre and D. Comar, 1984, Ro 15 1788 a specific radioligand for 'in vivo' central benzodiazepine receptor study by positron emission tomography, Int. J. Appl. Radiat. Isot. 35, 973.
26. Mazoyer, B.M., 1991, Investgation of the dopamine system with positron emission tomography: general issues in modelling, in: Brain Dopaminergic Systems: Imaging with Positron Tomography, eds. J.C. Baron, D. Comar, L. Farde, J.L. Martinot and B. Mazoyer (Kluwer Academic Publishers) p. 198.
27. Miller, L.G., D.J. Greenblatt, S.M. Paul and R.I. Shader, 1987, Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions, J. Pharmacol. Exp. Ther. 240, 516.
28. 11C]Ro 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET, J. Cereb. Blood Flow Metab. 8, 304.
29. Pauli, S., L. Farde, L. Halldin and G. Sedvall, 1991, Occupancy of the central benzodiazepine receptors during benzodiazepine treatment determined by PET, Eur. J. Neuropsychopharmacol. 1, 229.
30. 11C]Ro 15-3890: a PET study in healthy volunteers, J. Cereb. Blood Flow Metab. Suppl. 1, S122.
31. 11C]flumazenil and PET: equilibrium and kinetic methods, J. Cereb. Blood Flow Metab. 11, Suppl. 2, S612.
32. 11C]Ro 15 1788 a benzodiazepine antagonist studied in human brain in vivo by positron emission tomography, Eur. J. Pharmacol. 110, 247.
33. Savic, I., P. Roland, G. Sedvall, A. Persson, S. Pauli and L. Widen, 1988, In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci, Lancet II, 863.
34. Shinotoh, H., T. Yamasaki, O. Inoue, T. Itoh, K. Suzuki, K. Hashimoto, Y. Tateno and H. Ikehira, 1986, Visualization of specific binding sites of benzodiazepine in human brain, J. Nucl. Med. 27, 1593.
35. Shinotoh, H., M. Iyo, T. Yamada, O. Inoue, K. Suzuki, T. Itoh, H. Fukuda, T. Yamasaki, Y. Tateno and K. Hirayama, 1989, Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography, Human Psychopharmacol. 99, 202.
36. Spielberger, C.D., 1983, Manual for the state-trait anxiety inventory (form-Y)-('Self-evaluation questionnaire'), 1983, Consulting Psychologists Press Inc.
37. 11C]Ro 15 1788 after intravenous administration in man, Human Psychopharmacol. 4, 297.
38. Talairach, J. and P. Tournoux, 1988, Co-planar Stereotaxic Atlas of the Human Brain 3-Dimensional Proportional System: an Approach to Cerebral Imaging (Georg Thiem, Stuttgart) p. 122.
39. 123I]Iomazenil, Eur. J. Pharmacol. 249, 43.
40. Zivkovic, B., G. Perrault, E. Morel and D.J. Sanger, 1988, Comparative pharmacology of zolpidem and other hypnotics and sleep inducers, in: Imidazopyridines in Sleep Disorders, eds. J.P. Sauvanet, S.Z. Langer and P.L. Morselli (Raven Press, New York) p. 97.
41. Zivkovic, B., G. Perrault and D.J. Sanger, 1992, Receptor subtype selective drugs: a new generation of anxiolytics and hypnotics, in: Target receptors for anxiolytics and hypnotics: from molecular pharmacology to therapeutics, eds. J. Mendlewicz and G. Racagni (Karger, Basel) Vol. 3, p. 55.